Abstract 3825
Background
Recently, germline PVs in 20 cancer predisposition genes were found in 11.8% of patients with aPC in a multi-center study (Pritchard et al, NEJM 2017).These PVs appeared to be predictive of response to PARP inhibitors (PARPi). We sought to evaluate the prevalence of clinically actionable PVs in a comparable aPC cohort and investigate possible associations of PVs with baseline patient and disease characteristics.
Methods
Clinical data and germline DNA samples from 352 consecutive aPC patients were retrospectively collected. A custom target panel (Qiagen QiaSeq V3) composed of 35 genes deemed clinically actionable and/or included in the Pritchard publication were sequenced on an Illumina HiSeq2500. GATK best practices were followed for alignment and variant calling. Variants were filtered based on ClinVar pathogenicity and reviewed by genetic counselors to confirm clinical significance. Baseline patient characteristics were compared using the Chi-squared, Fisher’s, and Mann-Whitney U tests.
Results
Clinically actionable, germline PVs were found in 26/352 (7.4%) of this aPC cohort. 11 of the 26 mutation carriers had a PV in BRCA1, BRCA2, or ATM (overall prevalence 3.1%). 96.6% of men were Caucasian of North European descent. Baseline characteristics were similar in those with or without PVs in clinically actionable genes, including age at diagnosis (p = 0.77), Gleason score (p = 0.22), or presence of metastatic disease at diagnosis (p = 0.08).
Conclusions
Our aPC cohort appears to have a lower prevalence of clinically actionable, germline PVs than previously reported studies. These findings may help inform recommendations for clinical genetic testing in this population, and help estimate the pace of enrollment on multiple ongoing clinical trials with PARPi in this population.
Clinical trial identification
Legal entity responsible for the study
Huntsman Cancer Institute and University of Utah.
Funding
Has not received any funding.
Editorial Acknowledgement
N/A
Disclosure
N. Agarwal: Consultancy: Pfizer, Novartis, Merck, Genentech, Eisai, Exelixis, Clovis, EMD Serono. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract